Filing Flows

Filing Flows › CytomX Therapeutics (CTMX) › Next earnings date

CytomX Therapeutics (CTMX) earnings: missed the estimate

CytomX Therapeutics (CTMX) reported on Nov 5, 2026 and missed the EPS estimate: −$0.09 against −$0.07 (-27.2%). Revenue was $1.7M for Q3 2026, -72% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result−27.2% vs estimate
Beat rate40%

The last report

CytomX Therapeutics reported revenue of $1.7M for the third quarter 2026 (-72% Y/Y), net loss $20.0M. How it makes money → · Every quarter →

CytomX Therapeutics: EPS against the estimate, last 5 reportsCytomX Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.04−$0.09Nov 25−$0.09−$0.22Mar 26−$0.11−$0.10May 26−$0.10−$0.09Aug 26−$0.07−$0.09Nov 26
Latest (Nov 26): Estimate −$0.07, Reported −$0.09.

CytomX Therapeutics' latest quarter

CytomX Therapeutics, Q3 2026: revenue $1.7M (-72% year over year), net loss $20.0M, operating cash flow $16.6M. The chart follows the revenue to costs, profit and cash.

Questions

Did CytomX Therapeutics beat earnings?

CytomX Therapeutics (CTMX) reported on Nov 5, 2026 and missed the EPS estimate: −$0.09 against −$0.07 (-27.2%).

When does CTMX report earnings?

The next date is not set yet.

Does CytomX Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.